RIGL

$48.86-3.30%visit website

RIGEL PHARMACEUTICALS INC

Market Cap

$913M

Live price × SEC shares (Jul 30, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.27

60mo monthly vs SPY

P/E (TTM)

2.9

TTM to Jun 2026 · diluted EPS

P/S (TTM)

3.3

TTM to Jun 2026 · revenue

P/B

2.1

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	69,462	69,802	58,818	78,703	276,785
Cost of revenue	4,753	5,955	4,606	8,525	23,839
Research & development	7,353		11,676	13,961
Selling, general & administrative	28,936	29,992	30,651	32,642	122,221
Operating income	28,420	23,170	11,885	23,575	87,050
Interest expense	1,894		1,433	779
Pretax income	27,620	22,714	11,657	23,585	85,576
Income tax	(280)	(245,351)	3,003	6,295	(236,333)
Net income	27,900	268,065	8,654	17,290	321,909
EPS (basic) ($)	1.55		0.47	0.93	17.82
EPS (diluted) ($)	1.46		0.44	0.88	16.89
Weighted avg. shares (basic)	18,038		18,412	18,541
Weighted avg. shares (diluted)	19,156		19,686	19,570

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 4, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 61 more quarters, back to Jun 2010, with Tormere Pro.

Corporate Events (8-K)

12 filings in 12 months · 1 with priority itemsFull history →

Filed	Items	Filing
Aug 4, 2026 accepted 4:10 PM ET	2.02Earnings release	Document SEC ↗
Jul 1, 2026 accepted 4:11 PM ET	5.02Officer / director change	Document SEC ↗
Jun 17, 2026 accepted 4:05 PM ET	2.01Acquisition / disposition	Document SEC ↗
May 20, 2026 accepted 4:10 PM ET	5.02Officer / director change5.07Shareholder vote	Document SEC ↗
May 12, 2026 accepted 5:24 PM ET	1.01Material agreement	Document SEC ↗
May 5, 2026 accepted 4:08 PM ET	2.02Earnings release	Document SEC ↗
Apr 21, 2026 accepted 4:18 PM ET	1.02Agreement terminated	Document SEC ↗
Mar 3, 2026 accepted 4:11 PM ET	2.02Earnings release	Document SEC ↗
Feb 3, 2026 accepted 4:01 PM ET	5.02Officer / director change	Document SEC ↗
Jan 12, 2026 accepted 8:15 AM ET	2.02Earnings release8.01Other events	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

68%

W/W +13.3pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-06-22	2026-06-24	Ali-Jackson Kamil	Director	Sale	2,500	$35.00	$88K	10.1K	View
2026-05-26	2026-05-28	Ali-Jackson Kamil	Director	Sale	2,500	$29.17	$73K	12.6K	View
2026-02-20	2026-02-24	MOOS WALTER H	Director	Sale	4,000	$36.36	$145K	12.7K	View